For Healthcare Professionals
Advancing Skin Cancer Detection with Clinical Evidence
At SkinVision, our mission is to improve early skin cancer detection through robust, peer-reviewed clinical research, supported by large-scale real-world validation.
GDPR Compliant
ISO 13485 Certified
CE Class lla MDR Approved
Featured Clinical Studies
Peer-reviewed research demonstrating clinical validity and real-world impact
Validation Study
The ACCURACY Study
Dermatology, 2022 | Sangers T et al.
To validate the diagnostic accuracy of the SkinVision app, which uses a convolutional neural network (CNN) to detect premalignant and malignant skin lesions
Lesions asesessed
785
Sensitivity
86.9%
Specificity
80.1%
View Full Study
Real-World Evidence
Healthcare Claims Study
NPJ Digital Medicine, 2023 | Smak Gregoor et al.
To assess the impact of the SkinVision app on dermatological healthcare consumption in a population-based setting.
SkinVision users
18,960
Matched non-users
56,880
(Pre) malignant lesion claims
+32%
View Full Study
Research Pipeline
At SkinVision, our commitment to continuous improvement is driven by ongoing research and the integration of real-world data. We are actively refining our AI algorithm through targeted investigations that focus on:
1
High-risk lesion detection
2
Performance across diverse skin types and demographics
3
Longitudinal studies evaluating long-term outcomes
4
Market access
Upcoming studies
2025 - 2028
Cost-effectiveness projects
HE modeling and large data collections, Investigator initiated
Status: In Progress
2025 - 2027
Darker skin type (IV - VI) data collection
Investigator initiated
Status: Planned
For clinical related questions and information, please contact our clinical team Valentina Barone and Wim Laloo
clinical.affairs@skinvision.com